Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
Condition(s):NeutropeniaLast Updated:October 26, 2018Completed
Hide Studies Not Open or Pending
Condition(s):NeutropeniaLast Updated:October 26, 2018Completed
Condition(s):Healthy Adult SubjectsLast Updated:November 13, 2020Completed
Condition(s):Bacterial InfectionsLast Updated:November 21, 2023Completed
Condition(s):HealthyLast Updated:July 3, 2023Completed
Condition(s):Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)Last Updated:April 9, 2021Completed
Condition(s):Breast Neoplasms; Neoplasm MetastasisLast Updated:December 21, 2023Completed
Condition(s):Esophageal Neoplasm; Esophageal Diseases; Esophageal Squamous Cell CarcinomaLast Updated:October 14, 2020Unknown status
Condition(s):Recurrent Non Small Cell Lung CancerLast Updated:February 1, 2019Terminated
Condition(s):PharmacokineticsLast Updated:July 18, 2023Not yet recruiting
Condition(s):HealthyLast Updated:July 11, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.